Table 3 Patients’ characteristics
From: Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer
| Â | RAS p21 | ||
|---|---|---|---|
Total | RAS p21 elevated n (%) | p-value | |
Overall | 251 | 29 (12%) | Â |
ER status | Â | Â | 0.611 |
 Negative | 76 | 10 (13%) |  |
 Positive | 174 | 19 (11%) |  |
PR status | Â | Â | 0.358 |
 Negative | 101 | 14 (14%) |  |
 Positive | 149 | 15 (10%) |  |
HER2 status | Â | Â | 0.873 |
 Negativea | 143 | 18 (13%) |  |
 Positiveb | 76 | 9 (12%) |  |
Tumor subtype | Â | Â | 0.728 |
 Triple-negative | 37 | 6 (16%) |  |
 HR-positive HER2-negative | 106 | 12 (11%) |  |
 HER2-positive | 76 | 9 (12%) |  |
Metastatic site | Â | Â | 0.482 |
 Visceral | 98 | 13 (13%) |  |
 Bone | 35 | 2 (6%) |  |
 Both | 118 | 14 (12%) | |
Extent of metastatic disease | Â | Â | 0.768 |
 One site | 84 | 9 (11%) |  |
 Multiple sites | 167 | 20 (12%) |  |
Therapeutic setting | Â | Â | 0.249 |
 1st-line | 98 | 8 (8%) |  |
 2nd-line | 66 | 11 (17%) |  |
 3rd-line or more | 86 | 10 (12%) |  |
Grading | Â | Â | 0.604 |
 G1 | 5 | 1 (20%) |  |
 G2 | 129 | 13 (10%) |  |
 G3 | 103 | 14 (14%) | |
Circulating tumor cells | Â | Â | 0.101 |
  < 5 CTCs / 7.5 ml | 122 | 17 (14%) |  |
  ≥ 5 CTCs / 7.5 ml | 121 | 9 (7%) |  |